Cultiva Hanfexpo 2026

Europe's Cannabis Market Enters Major Growth Phase

The European medical cannabis market was valued at roughly $3.06 billion in 2025 and is projected to climb to more than $13.1 billion by 2034, representing strong double-digit annual growth . Other industry estimates suggest Europe's legal cannabis sector could reach between €2 billion and €4 billion within the next few years as regulations evolve and patient adoption accelerates . The market is entering a critical transition period as medical access programs expand, telemedicine accelerates patient adoption, and EU GMP standards reshape supply chains

EU CBD Novel Food Regulation Creates Market Uncertainty

The European Commission issued multiple implementing decisions in February 2026 terminating procedures for authorising various CBD and cannabidiol products (including NF/2022/11411, NF/2020/2144, NF/2021/0044, NF/2022/2730, NF/2022/11451) as novel foods without updating the Union list . This has created significant regulatory uncertainty for CBD edible products across the EU. France began removing edible CBD products from sale on 15 May 2026 under EU novel food rules- , with EFSA setting a provisional safe intake level of 2mg/day while its novel food evaluations remain on hold

EU-GMP Compliance and Supply Chain Standardisation

EU GMP standards are increasingly becoming a defining factor for companies seeking long-term participation in European medical cannabis markets . International cannabis trade into Europe continues accelerating, with imports flowing from Canada, Portugal, Latin America, Africa, Australia, and other emerging supply regions - . The industry is maturing in a much more structured and pharmaceutical-style environment compared to earlier North American markets, with licensed operators gaining competitive advantage through strict compliance